ArticleNeuropsychopharmacology reports2026
Increased Cerebrospinal Fluid Lactate Levels in Schizophrenia and Major Depressive Disorder: NCNP Biobank Study in Japan.
Article in Neuropsychopharmacology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- State-Dependent Transcriptomic Collapse of the Brain's Lactate and Ketone Thermodynamic Sensors in Schizophrenia.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
aimAltered brain energy metabolism related to neural hyperexcitation, which leads to increased lactate levels in the brain and cerebrospinal fluid (CSF), has been implicated in several neuropsychiatric disorders. This study aimed to investigate CSF levels of lactate and related metabolites in Japanese individuals with schizophrenia and major depressive disorder (MDD), using samples from the National Center for Neurology and Psychiatry biobank.
methodsCSF levels of lactate, pyruvate, and glucose were measured in 27 patients with schizophrenia, 26 patients with MDD, and 27 age-matched non-psychiatric controls. Analyses were conducted by diagnostic groups and demographic variables.
resultsCSF lactate levels were significantly higher in individuals with schizophrenia and MDD compared with controls. CSF glucose levels were significantly elevated in individuals with MDD compared with controls. Pyruvate levels showed no significant group differences. Across all individuals, CSF lactate, pyruvate, and glucose levels were positively correlated. Lactate and glucose levels showed positive correlations with age. No significant associations were found between the three metabolites' levels and medication dosages, except for an effect of imipramine on glucose levels.
conclusionThis study confirmed elevated CSF lactate levels in Japanese individuals with schizophrenia and MDD, consistent with findings in other populations. The elevation of CSF lactate is unlikely to reflect medication effects and instead may represent an underlying pathophysiology associated with altered brain energy metabolism in the brain.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.